CFDA Approves Venus Medtech's TAVR Device

China–based Venus Medtech has received approval from the China Food and Drug Administration (CFDA) for its Venus A-valve.

The company’s transcatheter aortic valve system, Venus A-valve, provides a less invasive treatment solution for inoperable and high-risk patients.

The study showed the implantation success rate was 95 percent and the 30-day all-cause mortality was 5 percent.

The company will launch a global trial for the third generation TAVR device at the end of 2017. — Cynthia Jessup